The Role of Histone Demethylase in Osteogenic and Chondrogenic Differentiation of Mesenchymal Stem Cells: A Literature Review

SUI Hao, ZHANG Tao

Abstract

The proliferation and multi-directional differentiation potential of mesenchymal stem cells (MSCs) enabled its wide use in the development of new therapies for bone and cartilage repair. Although preliminary work has been done to verify the gene expression profile of MSCs osteogenic and chondrogenic differentiation, it is still unclear what key factors initiate the differentiation of MSCs, resulting in its limited application in bone and cartilage tissue engineering. The epigenetic mechanism mediated by histone demethylases (lysine [K]-specific histone demethylases, KDMs) is the key link in regulating MSCs lineage differentiation. The lysine-specific histone demethylase (LSD) family containing Tower domain and the histone demethylase family containing Jumonji C (JmjC) domain regulate the expression of various osteogenic-related genes, including Runt-related transcription factor 2 (RUNX2), osterix (OSX), osteocalcin (OCN), to mediate MSCs osteogenic differentiation. The KDM2/4/6 subfamilies regulate the chondrogenic differentiation of MSCs through multiple pathways centered on SRY-related high-mobility-group-box gene 9 (SOX9). In addition, nanotopology, mircoRNAs, etc. regulate the expression of a variety of osteogenic and chondrogenic transcription factors through up- and down-regulation of KDMs. In summary, the role of histone demethylase in the osteogenic and chondrogenic differentiation of mesenchymal stem cells will help us better understand the pathogenesis of bone and cartilage damage diseases, and establish the foundation of future clinical applications for bone and cartilage tissue engineering.

 

Keywords: Mesenchymal stem cells, Histone demethylase, Epigenetics, Osteogenic differentiation, Chondrogenic differentiation

 

Full Text:

PDF


References


ANKRUM J A， ONG J F， KARP J M. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol，2014，32(3): 252–260.

DOMINICI M， BLANC K L， MUELLER I， et al. Minimal criteria for defining multipotent mesenchymal stromal cells. Cytotherapy，2006，8(4): 315–317.

CAPLAN A I. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol，2010，213(2): 341–347.

MINGUELL J J， ERICES A， CONGET P. Mesenchymal stem cells. Exp Biol Med (Maywood)，2001，226(6): 507–520.

ROMANOV Y A， DAREVSKAYA A N， MERZLIKINA N V， et al. Mesenchymal stem cells from human bone marrow and adipose tissue: isolation, characterization, and differentiation potentialities. Bull Exp Biol Med，2005，140(1): 138–143.

OZKUL Y， GALDERISI U. The impact of epigenetics on mesenchymal stem cell biology. J Cell Physiol，2016: 2393–2401[2020-12-20]. https://doi.org/10.1002/jcp.25371.

MA S， XIE N， LI W， et al. Immunobiology of mesenchymal stem cells. Cell Death Differ，2014，21(2): 216–225.

NÉMETH K， LEELAHAVANICHKUL A， YUEN P S T， et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med，2008，15(1): 42–49.

YUAN Y， LIN S， GUO N， et al. Marrow mesenchymal stromal cells reduce methicillin-resistant Staphylococcus aureus infection in rat models. Cytotherapy，2014，16(1): 56–63.

WARD C L， SANCHEZ JR C J， POLLOT B E， et al. Soluble factors from biofilms of wound pathogens modulate human bone marrow-derived stromal cell differentiation， migration， angiogenesis， and cytokine secretion. BMC Microbiol， 2015， 15: 75[2020-12-20]. https://doi.org/10. 1186/s12866-015-0412-x.

WALTER J， WARE L B， MATTHAY M A. Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. Lancet Respir Med，2014，2(12): 1016–1026.

DRAGOJEVIČ J， LOGAR D B， KOMADINAET R， et al. Osteoblastogenesis and adipogenesis are higher in osteoarthritic than in osteoporotic bone tissue. Arch Med Res，2011，42(5): 392–397.

HOSHIBA T， KAWAZOE N， CHEN G. The balance of osteogenic and adipogenic differentiation in human mesenchymal stem cells by matrices that mimic stepwise tissue development. Biomaterials，2012，33(7): 2025–2031.

RISBUD M V， SITTINGER M. Tissue engineering: advances in in vitro cartilage generation. Trends Biotechnol，2002，20(8): 351–356.

AISENBREY E， BRYANT S. A MMP7-sensitive photoclickable biomimetic hydrogel for MSC encapsulation towards engineering human cartilage. J Biomed Mater Res A，2018，106(8): 2344–2355.

TAKADA I， KOUZMENKO A P， KATO S. Wnt and PPARγ signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol，2009，5(8): 442–447.

CHANG J， WANG Z， TANG E， et al. Inhibition of osteoblastic bone formation by nuclear factor-κB. Nat Med，2009，15(6): 682–689.

MOERMAN E J， TENG K， LIPSCHITZ D A， et al. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell，2004，3(6): 379–389.

LEE H L， YU B， DENG P， et al. Transforming growth factor-β-induced KDM4B promotes chondrogenic differentiation of human mesenchymal stem cells. Stem Cells，2016，34(3): 711–719.

LIM K E， PARK N R， CHE X， et al. Core binding factor β of osteoblasts maintains cortical bone mass via stabilization of Runx2 in mice. J Bone Miner Res，2015，30(4): 715–722.

GEARHART M D， CORCORAN C M， WAMSTAD J A， et al. Polycomb group and SCF ubiquitin ligases are found in a novel BCOR complex that is recruited to BCL6 targets. Mol Cell Biol，2006，26(18): 6880–6889.

ATLASI Y， STUNNENBERG H G. The interplay of epigenetic marks during stem cell differentiation and development. Nat Rev Genet，2017， 18(11): 643–658.

PORTELA A， ESTELLER M. Epigenetic modifications and human disease. Nat Biotechnol，2010，28(10): 1057–1068.

VINCENT A， SEUNINGEN I V. Epigenetics, stem cells and epithelial cell fate. Differentiation，2009，78(2/3): 99–107.

CANTERBURY E， DURAIAPPAH A K， NAEEM S， et al. Translating the histone code. Science，2001，293(5532): 1074–1080.

LUNYAK V V， ROSENFELD M G. Epigenetic regulation of stem cell fate. Hum Mol Genet，2008，17(R1): R28–R36.

SHI Y， LAN F， MATSON C， et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell，2004，119(7): 941–953.

NIC-CAN G I， RODAS-JUNCO B A， CARRILLO-COCOM L M， et al. Epigenetic regulation of adipogenic differentiation by histone lysine demethylation. Int J Mol Sci，2019，20(16): 3918[2020-12-09]. https://doi.org/10.3390/ijms20163918.

GE W， LIU Y， CHEN T， et al. The epigenetic promotion of osteogenic differentiation of human adipose-derived stem cells by the genetic and chemical blockade of histone demethylase LSD1. Biomaterials，2014， 35(23): 6015–6025.

DU J， MA Y， MA P， et al. Demethylation of epiregulin gene by histone demethylase FBXL11 and BCL6 corepressor inhibits osteo/dentinogenic differentiation. Stem Cells，2013，31(1): 126–136.

YU G， WANG J， LIN X， et al. Demethylation of SFRP2 by histone demethylase KDM2A regulated osteo-/dentinogenic differentiation of stem cells of the apical papilla. Cell Prolif，2016，49(3): 330–340.

DENG Y， GUO T， LI J， et al. Repair of calvarial bone defect using jarid1a-knockdown bone mesenchymal stem cells in rats. Tissue Eng Part A，2018，24(9/10): 711–718.

FAN Z， YAMAZA T， LEE J S， et al. BCOR regulates mesenchymal stem cell function by epigenetic mechanisms. Nat Cell Biol，2009，11(8): 1002–1009.

QI Q， WANG Y， WANG X， et al. Histone demethylase KDM4A regulates adipogenic and osteogenic differentiation via epigenetic regulation of C/EBPα and canonical Wnt signaling. Cell Mol Life Sci， 2020，77(12): 2407–2421.

YE L， FAN Z， YU B， et al. Histone demethylases KDM4B and KDM6B promotes osteogenic differentiation of human MSCs. Cell Stem Cell， 2012，11(1): 50–61.


Refbacks

  • There are currently no refbacks.